Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 exon 14 ins FLT3 N676D |
Therapy | Ningetinib |
Indication/Tumor Type | hematologic cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins FLT3 N676D | hematologic cancer | sensitive | Ningetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Ningetinib (CT053PTSA) inhibited viability in a cell line expressing a FLT3-ITD and FLT3 N676D in culture (PMID: 38978049). | 38978049 |
PubMed Id | Reference Title | Details |
---|---|---|
(38978049) | Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia. | Full reference... |